Piper Says Buy Alnylam Sell-Off Today For Late September Data Release
September 07, 2017 at 13:40 PM EDT
Analyst Edward Tenthoff lowered his price target for Alnylam Pharmaceuticals to $110 from $126 after the company said it discontinued dosing of fitusiran in all ongoing studies following a fatal thrombotic event in a Hemophilia A patient.
